The Role of Denosumab in the Treatment of Primary Tumors of Bone.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37032292.
- Also identified by DOI 10.1016/j.jhsa.2023.02.013 and PMC identifier 11134346.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand.
Medical subject headings
- Bone Density Conservation Agents
- Giant Cell Tumor of Bone
- Bone Neoplasms